Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar

A biosimilar product needs to demonstrate biosimilarity to the originator reference product, and the quality profile of the latter should be monitored throughout the period of the biosimilar's development to match the quality attributes of the 2 products that relate to efficacy and safety. For...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :MAbs
Главные авторы: Kim, Seokkyun, Song, Jinsu, Park, Seungkyu, Ham, Sunyoung, Paek, Kyungyeol, Kang, Minjung, Chae, Yunjung, Seo, Heewon, Kim, Hyung-Chan, Flores, Michael
Формат: Artigo
Язык:Inglês
Опубликовано: Taylor & Francis 2017
Предметы:
Reports
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5419076/
https://ncbi.nlm.nih.gov/pubmed/28296619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2017.1305530
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы